6 completed, 1 enrolling by invitation, 1 recruiting. 5 Not applicable, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 5 | Completed 4, Enrolling by invitation 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
Follow Glucose-dependent Insulinotropic Polypeptide (GIP): new trials by email Literature Review of Glucose-dependent Insulinotropic Polypeptide (GIP) trials Research Report on Glucose-dependent Insulinotropic Polypeptide (GIP)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Antiemetic Effects of Increased Splanchnic Perfusion, Induced by the Gut Hormone GIP, in Healthy Individuals Glucose-dependent Insulinotropic Polypeptide (GIP), GLP-1 (7-36) amide, Apomorphine Injectable Solution - Emesis | Not applicable | Enrolling by invitation | University of Copenhagen | 14 | 2026-05-19 | 2026-07-07 |
| A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese Glucose-dependent Insulinotropic Polypeptide (GIP), Cagrilintide, Placebo GIP - Overweight, Obese | Phase 1 | Recruiting | Novo Nordisk A/S | 100 | 2026-02-09 | 2026-04-13 |
| Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA) Glucose-dependent Insulinotropic Polypeptide (GIP) - Bone Disease, Metabolic, Diabetes Mellitus, Type 2 | Not applicable | Completed | Esbjerg Hospital - University Hospital of Southern Denmark | 13 | 2025-11-10 | 2026-10-01 |
| The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes Glucose-dependent Insulinotropic Polypeptide (GIP), alanine, Saline (NaCl 0,9 %) (placebo) - Type 1 Diabetes | Not applicable | Completed | Asger Lund, MD | 10 | 2025-01-01 | 2026-04-29 |
| The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes Semaglutide 1.34 MG/ML [Ozempic], Glucose-dependent insulinotropic polypeptide (GIP), Semaglutide 1.34 mg/ml placebo - Type 2 Diabetes, Obesity | Not applicable | Completed | Asger Lund, MD | 61 | 2022-01-27 | 2025-03-14 |
| Effects of Gut Peptides on Bone Remodeling Glucagon-Like Peptide-2 (GLP-2), Glucose-dependent insulinotropic polypeptide (GIP), GLP-2+GIP - Healthy | Not applicable | Completed | University of Copenhagen | 10 | 2018-06-01 | 2021-01-20 |
| Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25 - Type 2 Diabetes Mellitus | Phase 1 | Completed | Washington University School of Medicine | 38 | 2009-10-01 | 2014-07-22 |
| Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25 - Diabetes | Phase 1 | Completed | Washington University School of Medicine | 40 | 2008-12-01 | 2018-05-03 |
Diabetes Mellitus, Type 2 (3) · Obesity (3) · Diabetes Mellitus (2) · Insulin Resistance (2) · Bone Diseases, Metabolic (1) · Diabetes Mellitus, Type 1 (1) · Nausea (1) · Overweight (1) · Vomiting (1)
Asger Lund, MD (2) · University of Copenhagen (2) · Washington University School of Medicine (2) · Esbjerg Hospital - University Hospital of Southern Denmark (1) · Novo Nordisk A/S (1)
Denmark (5) · United States (2) · United Kingdom (1)
Burton Wice, PhD (2) · Dominic Reeds, MD (2)
PMID 22522617, PMID 24183983, PMID 24356886, PMID 36849212, PMID 42173109, PMID 42712058
1RC1DK086163-01 (1), R01DK088126 (1)